Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III Antibiotic Garenoxacin Will Be Out-Licensed, Schering Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering-Plough will out-license U.S. rights to the Phase III quinolone antibiotic garenoxacin due to potential conflicts of interest related to the company's primary care marketing agreement with Bayer
Advertisement

Related Content

Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
Schering-Plough Drops Garenoxacin NDA, But Leaves Door Open For Resubmission
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
Schering’s Antibiotic Garenoxacin Gets Advisory Committee Date
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Schering-Plough Licensing Toyama Antibiotic Garenoxacin, Picking Up Where Bristol Left Off

Topics

Advertisement
UsernamePublicRestriction

Register

PS062049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel